Sunday, 31 May 2015

G-Protein Coupled Receptors (GPCRs) Market Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2022


This report on G-protein coupled receptors (GPCRs) market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies engaged in manufacturing and commercialization of GPCR assays, cell lines, and consumables and entrants that are planning to invest in the GPCRs market. This report comprises an elaborate executive summary, which includes a market snapshot providing overall information of various segments and sub-segments included in the study scope. This section also provides overall information and data analysis of the global GPCRs market with respect to the leading market segments based on types of products, applications and geographic regions.

Browse Full G-Protein Coupled Receptors (GPCRs) Market Report With Complete TOC @


The global GPCRs market has been segmented based on of assay type, therapeutic area, and geography. Based on assay type, the GPCRs market has been categorized into six major segments: cAMP assays, calcium level detection assays, GTPγS binding assays, reporter gene assays, receptor internalization assays, and cGMP assays. The market for these segments has been extensively analyzed based on of their effectiveness, usefulness, sales, and geographic presence. Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year.

In terms of therapeutic areas, the market has been segmented into seven categories: cardiovascular system, central nervous system (CNS), respiratory system, immune system, reproductive system, oncology, and others (abdominal, urinary, orthopedics, etc.). Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year.

The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that have strong impact on the GPCRs market currently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. Porter’s Five Forces analysis is also explained in this section to understand the GPCRs market considering different parameters that have an impact on the sustainability of the companies operating in the GPCRs market. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market.



Geographically, the GPCRs market has been categorized into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). Major geographic regions have been further divided into major national markets, viz. North America (the U.S. and Canada), Europe (Germany, the U.K., France, and Rest of Europe), and Asia Pacific (China, Japan, India, and Rest of Asia Pacific). Moreover, Rest of the World has been further subdivided into three regions: Latin America, the Middle East, and Africa. Market revenue in terms of USD million for the period between 2012 and 2022 along with the CAGR % from 2014 to 2022 are provided for all the regional and national markets considering 2013 as the base year.

The recommendations section included in the report would assist existing market players in expanding their market shares and new companies in establishing their presence in the global market. The report also profiles major players in the GPCRs market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include Thermo Fisher Scientific, Inc., EMD (Merck) Millipore, Becton, Dickinson and Company, PerkinElmer, Inc., Cisbio Bioassays, Enzo Life Sciences, Inc., DiscoveRx Corporation, Sigma-Aldrich Corporation, QIAGEN N.V., Promega Corporation, Abcam plc, and HD Biosciences Co. Ltd.

The global GPCRs market is segmented as follows:

GPCRs Market, by Assay Type
Calcium Level Detection Assays
GTPγS Binding Assays
cGMP Assays
Reporter Gene Assays
Receptor Internalization Assay
cAMP Assays
GPCRs Market, by Therapeutic Area
Cardiovascular System
Central Nervous System
Respiratory System
Immune System
Reproductive System
Oncology
Others
GPCRs Market, by Geography
North America
U.S.
Canada
Europe
U.K.
Germany
France
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Rest of the World (RoW)
Latin America
Middle East
Africa.



About Us

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Wednesday, 27 May 2015

Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market Trends and Forecast 2014 – 2020

Sterilizers, antiseptics, and chemical disinfectors are antimicrobial agents that are specifically used and applied in surgical and dental equipment as well as in living tissues to destroy or kill microorganisms that could infect and cross-contaminate the surgical site in patients. These chemical disinfectants are recurrently used in hospitals, dental clinics, and other health care settings to destroy and disinfect various infectious microorganisms that could increase the risk of hospital-acquired infection. This report provides market analysis for various chemical formulations used for sterilization and disinfection. The stakeholders of this report comprise established players involved in the development and distribution of chemical sterilizers and disinfectors as well as new players who wish to enter the Indian market.

Browse the full Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market Report at


This market study provides a complete analysis of the sterilizers and surgical, dental care and equipment disinfectors market in India and helps in identifying various market governing factors. The market overview section provides an in-depth analysis of the overall market trends and market dynamics such as drivers, restraints, and growth opportunities that currently direct the dynamics of the overall market. Additionally, the chapter recommends and predicts the future conditions of the market. Market strategy tool such as Porter’s Five Forces analysis has also been incorporated in this report to provide rational analysis about the level of competition within the sterilizers and surgical, dental care and equipment disinfectors market in India. The executive summary incorporated in this study summarizes the exhaustive insights about the study technique and the market. Moreover, it includes a market snapshot, which provides a glance into the current scenario of the sterilizers and surgical, dental care and equipment disinfectors market in India in terms of current and future market size and growth rate. Competitor analysis tools such as market share analysis and value chain analysis have also been included in the market overview section of the report to deliver a broad analysis of the overall market scenario in the sterilizers and surgical, dental care and equipment disinfectors market in India.

The sterilizers and surgical, dental care and equipment disinfectors market in India has been segmented based on chemical formulation, application, end-user, and surgery stage. The market is segmented into the major types of chemical formulations used to manufacture sterilizers and equipment disinfectors such as chlorhexidine gluconate based formulations, alcohol-based agents, povidone-iodine based formulations, benzalkonium chloride based formulations, octenidine hydrochloride based formulations, ethyl-hexadecyl-dimethyl ammonium based formulations and others (aldehydes, hydrogen peroxide, hypochlorites, and chlorine-based disinfectors). The report also studies the market in terms of application areas such as hospitals and veterinary care centers, where sterilizers and disinfectors are generally used. The hospitals segment has been sub-segmented into general hospitals and dental care centers. Furthermore, the general hospitals segment has been sub-segmented into wound care applications, burn care applications, and ulcer care applications. The dental care centers segment has been categorized into surgical care applications and diagnostics care applications. By end-users, the study includes patients and caregivers; hospital and nursing staff; operating rooms, ICUs and nursing tables; equipment and devices used during surgery, and others. Based on surgery stages, the market has been segmented into pre-operative, intra-operative, and post-operative stages. The market size and volume estimations for the period from 2012 to 2020 have been provided for each of the major formulations and applications mentioned above in terms of INR Crore and Tons. Along with the market size and volume estimations that were projected considering 2013 as the base year and 2012 as the historical year, the CAGR (%) of each market segment for the forecast period from 2014 to 2020 have also been provided.

Browse the full Press Release Report at



The study concludes with profiles of leading players as well as end-users of disinfectors (hospitals), which comprise business insights about the major companies actively involved in the sterilizers and surgical, dental care and equipment disinfectors market in India. The study profiles the market players in terms of company overview, financial overview, product portfolio, business strategies, and recent developments. Major enterprises profiled in this study include 3M, Advanced Sterilization Products Services, Inc., Antrix Hygiene Ltd., Ipca Laboratories Ltd., Medi-Vet Animal Health, LLC, PSK Pharma Private Limited, Raman & Weil Pvt. Ltd., Ranbaxy Laboratories Ltd., Reckitt Benckiser Group plc, Sanosil Biotech Pvt. Ltd., Schülke India Pvt. Ltd., UPS Hygienes Pvt. Ltd., Win-Medicare Pvt. Ltd., and Zep Superior Solutions. The end-users (hospitals) profiled in this study are Apollo Hospitals Enterprise Ltd., Fortis Healthcare Limited, and Wockhardt Hospitals. Market share analysis that has been provided in context with the disinfectant manufacturers operating in the market would help new entrants to understand the key business concepts and frameworks as well as to identify the product lines of the existing companies for strengthening their position in the overall market.

The India sterilizers and surgical, dental care and equipment disinfectors market is segmented into the following categories:
 
Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market, by Chemical Formulations
Chlorhexidine Gluconate Based Formulations
Alcohol Based Agents
Povidone-Iodine Based Formulations
Benzalkonium Chloride Based Formulations
Octenidine Hydrochloride Based Formulations
Ethyl - hexadecyl - dimethyl Ammonium Based Formulations
Others (Aldehydes, Hydrogen Peroxide, Hypochlorites and Chlorine Based Disinfectors)
Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market, by Applications
Hospitals
General Hospitals
Wound Care
Burn Care
Ulcer Care
Dental Care Centers
Surgical Care
Diagnostic Care
Veterinary Care Centers
Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market, by End-users
Patients and Caregivers
Hospital and Nursing Staff
Operating Rooms, ICUs and Nursing Tables
Equipment and Devices used during Surgery
Others (Veterinary and Diagnostic Care Centers)
Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market, by Surgery Stages
Pre-operative
Intra-operative
Post-operative




About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.


Posted by at No comments:
Labels:

Asia Pacific Region to Dominate the Global FMD Vaccines Market


Transparency Market Research has released a new report on the global foot and mouth disease (FMD) vaccines market, which forecasts the growth of the overall FMD vaccines market at a CAGR of 8.8% during the period from 2014 to 2020. The FMD vaccines market was valued at US$0.51 billion in 2013. Due to the increasing frequency of FMD outbreaks, the report projects that the market will reach a worth of US$0.95 billion by the end of 2020. The report is titled ‘Foot and Mouth Disease Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020’.

Browse the full Foot and Mouth Disease Vaccines Market Report at http://www.transparencymarketresearch.com/foot-mouth-disease-vaccines.html


Caused by Aphthovirus, FMD is highly infectious viral disease which affects cloven-hoofed animals and leads to high mortality rate among the young stock such as lambs and piglets. The high prevalence of FMD across the globe affects the international trade in livestock products. The report provides an overview of the overall global FMD vaccines market and evaluates the growth drivers and restraints. Favorable government initiatives to control FMD outbreaks have boosted the growth of the global FMD vaccines market. Also, rising consumption of meat and dairy products demands healthy livestock, which has further fuelled the need for FMD vaccines. The report mentions that the involvement by various governments in purchasing FMD vaccines will lead to the dip in cost which will negatively affect the global FMD vaccines market in terms of revenue. FMD is caused by seven different types of serotype and the current vaccines are serotype-specific. Unpredictable serotype outbreaks can hamper the growth of the global FMD vaccines market. The report indicates that DNA vaccines will open new opportunities for the market during the forecast period.

Depending upon the type of vaccines, the report segments the global FMD vaccines market into conventional vaccines and emergency vaccines. The conventional vaccines have been further categorized into aluminum hydroxide or Saponin based vaccines, and oil-based vaccines. In 2013, oil-based FMD vaccines dominated the global FMD vaccines market with a market share of 63%, owing to its high efficiency and longer effect in treating the disease.

On the basis of application on the livestock, the global FMD vaccines market has been divided into cattle, pigs, sheep and goats, and others. To meet the increasing demand for milk and meat, cattle are reared the most across the globe, owing to which it has emerged as the largest application segment of the global FMD vaccines market. In Middle-east, as pork consumption is prohibited, the cattle segments contribute significantly to the FMD vaccines market of the region. The report predicts that the cattle segment will exhibit the fastest growth during the forecast horizon.

Browse the full Press Release Report:

Geographically, the global FMD vaccines market has been segmented into four key regions: Europe, North America, Asia Pacific, and Rest of the World. As the disease is non-existent in North America and Europe, the scope of the growth of the vaccines market in these regions is negligible. Due to frequent outbreaks of FMD in Asia Pacific region, the global FMD vaccines market has been dominated by this region with more than 70% share. The report documents the market revenue in China, India, Malaysia, South Korea, and rest of APAC during the forecast period. The report profiles some of the key vendors of the global FMD vaccines market such as Indian Immunologicals Ltd., Bayer AG, Agrovet Co., and Brilliant Bio Pharma Ltd.



About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

North America Spearheading the Global Kidney Cancer Drugs Market

Kidney cancer is considered to be one of the 10 most common cancers affecting men and women across the globe. While the risk of kidney cancer is higher in men than in women, there are numerous factors that determine the risk of cancer. The two main types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC), and kidney cancer drugs are generally administered to patients of stage four, advanced RCC.

Browse Full Global Kidney Cancer Drugs Market Report With Complete TOC @ http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html


According to the American Cancer Society, in the year 2015, approximately 61,560 new cases of kidney cancer will be registered in the United States alone, of which 23,290 will be women and 38,270 will be men. Out of these, around 14,080 people will die from the disease in 2015, of which 5,010 will be women and 9,070 will be men.

The U.S. National Cancer Institute states that kidney cancer is more common among American Indian, African American, and Alaska Native populations. This makes North America a rather large and lucrative market for kidney cancer drugs.

Votrient: Most promising commercially available kidney cancer drug

There are a number of kidney cancer drugs that are prescribed, used, and commercially available today. Some of the major brands are Votrient (Pazopanib), Inlyta (Axitinib), Proleukin (Aldesleukin), Afinitor (Everolimus), Sutent (Sunitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), and Avastin (Bevacizumab).

Of these, Sutent (Sunitinib) dominated the kidney cancer drugs market in 2013, accounting for 30% of the revenue share. Often considered to be the first line of treatment for renal cell carcinoma (RCC), Sutent is one of the most studied kidney cancer drugs for multiple indications. However, owing to its relatively high price, this drug is expected to register a rather meager growth rate of 1.1% from 2012 to 2016 and 2.1% from 2016 to 2020.

Votrient (Pazopanib), on the other hand, is projected to be the most promising kidney cancer drug during the forecast period and will witness the strongest growth between 2012 and 2020. According to a report by Transparency Market Research (TMR), Votrient is estimated to grow at an outstanding CAGR of 41.7% from 2012 to 2016, and 8.9% from 2016 to 2020.

U.S. largest pharmaceutical market in the world

The global kidney cancer drugs market is divided into four key geographic regions: North America, Europe, Asia-Pacific, and Rest of the World. The growing prevalence of kidney cancer makes North America the leading market for kidney cancer drugs; revenue-wise, this region held more than 45% of the total share in 2013. Split into Canada and the United States, the North America market is driven by a growing patient pool, commercial availability of leading drugs for the treatment of kidney cancer, a strong healthcare insurance base, and impressive healthcare systems customized for the pharmaceutical sector. The U.S. accounted for 90% of the North America kidney cancer drugs market.

The APAC region has also proved to be a lucrative market for kidney cancer drugs owing to a rising geriatric population, growing prevalence of kidney cancer, and economic recovery and growth in countries such as China, Japan, Australia, and New Zealand. Registering a 6% growth rate, the Asia-Pacific market for kidney cancer drugs is anticipated to be the fastest growing regional segment during the forecast period.

Market to register healthy growth rate owing to intense competition

The recently-published TMR report has indicated that the market for kidney cancer drugs is characterized by strong competition among industry participants. With the global market being immensely consolidated, there are only a handful of established pharmaceutical companies who dominate the kidney cancer drugs market. Some of the principal players operating in the market are GlaxoSmithKline, plc, F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Bayer AG, and Novartis AG. Among these, Pfizer was the largest maker of kidney cancer drugs in the world and held more than 40% of the total market share in 2013.

The report states that this concentration of power in the hands of a few contributes to the growth of the kidney cancer drugs market. In 2013, the global market was valued at US$2.6 billion and this is estimated to reach US$4.5 billion by 2020, expanding at a compound annual growth rate of 6.6% till 2020.


About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Monday, 25 May 2015

Albumin (Excipient) Market Expected to Reach USD 0.8 Billion Globally in 2020


According to a new market report published by Transparency Market Research “Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast, 2014 - 2020,” the global albumin excipient market was valued at USD 704.9 million in 2013 and is expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an estimated value of USD 828.2 million by 2020.

Selection of appropriate excipients is very important during the development of drug formulations and vaccines. A suitable excipient helps stabilize and protect an active pharmaceutical ingredient (API) in the formulation against degradation, oxidation or aggregation that the API could undergo during manufacturing, transport and storage. As an excipient, albumin has wide applications in drug formulation, drug delivery, vaccine manufacturing and as a component of media for the production of vaccines. Manufacturers are increasingly considering innovative ways to reduce contamination risks of finished products due to the recent incidents of animal virus contamination of biopharmaceutical products. Manufacturers must adhere to strict regulations on the standards and also provide detailed information on the country of origin (BSE free), the types of tissue used and details of the manufacturing process during the compliance and approval procedure.

The global albumin market is analyzed by albumin type, applications and geography. On the basis of type, the market is segmented into human serum albumin, bovine serum albumin and recombinant albumin. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. The segment is expected to reach USD 557.0 million in 2020, growing at a CAGR of 2.2% during the forecast period between 2014 and 2020. Bovine serum albumin is used in the production of vaccines such as MMR II, Varivax, Zostavax and RotaTeq in ranges of less than 1 ppm. Extensive research to explore new ways is underway to increase virus yield and quality in manufacturing. Recently, end-user preference has been observed to have shifted towards recombinant human albumin (rAlbumin) used in multiple applications such as in nano formulation and drug carrier over specific therapeutic modalities. Advances in yeast-based protein expression and the successful scale-up have led to the development of an industrial-scale manufacturing process that can produce a highly pure, animal-free rAlbumin suitable for use as an excipient in biotherapeutics.

abumin-market

Primary applications of albumin include drug formulation and drug delivery, vaccines, and component of media. The drug formulation and drug delivery segment is expected to reach USD 395.9 million in 2020. Expansion of the role of albumin in drug delivery has widened the field of nanotechnology as well. For instance, Abraxis BioScience has applied nanotechnology to human serum albumin (HSA) with its nanoparticle albumin-bound, known as ‘NAB’ technology platform. This approach combines HSA with an API for delivering protein drugs.

Geographically, North America continues to dominate the market due to high demand for albumin in drug formulations, and research and development activities. The albumin market in the region was valued at USD 253.8 million in 2013. The current focus of the research community in most of the academic institutions and industry is to use albumin as a carrier for micro- and nanoparticles for sustained-release injectable drugs. Paclitaxel nano-particulate formulation containing albumin as a carrier was approved by the U.S. FDA in September 2013. Countries such as China, India and Australia exhibit significant growth prospects in terms of rapid increase in the research collaboration between industry and research institutions. GlaxoSmithKline Pharmaceuticals Limited (GSK) is funding around USD 4 million per year to initiate research and development program with the leading research institutions in Asia Pacific for the development of potential therapeutics.

Some of the major companies operating in the global albumin market are CSL Behring, HiMedia, InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fischer Scientific, Inc. and MedxBio Pte. Ltd. Pharmaceutical companies and research institutes obtain the desired albumin excipient grade from the market players for their development activities. The key players in the global albumin market improve their distribution network by entering into strategic alliances and distributorship agreements. For instance, InVitria partnered with Thermo Fischer Scientific and Sigma-Aldrich in order to provide its customers with product support best tailored to meet their needs. InVitria has distributors across the world including North America, Europe, Asia and Australia.

Browse the full Albumin (Excipient) Market (Types: Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin; Applications: Drug Formulation and Drug Delivery, Vaccines, and Component of Media) - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast, 2014 - 2020 report at http://www.transparencymarketresearch.com/albumin-market.html


The global albumin market is segmented as follows:
Albumin Market Revenue (USD Million), by Type
Human Serum Albumin
Bovine Serum Albumin
Recombinant Albumin
Albumin Market Revenue (USD Million) and Volume (kg), by Application
Drug Formulation and Drug Delivery
Vaccines
Component of Medium
Albumin Market Revenue (USD Million) and Volume (kg), by Geography
North America
Europe
Asia Pacific
Rest of the World



About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/
Posted by at No comments:
Labels:

Human Papillomavirus and Cytomegalovirus Therapeutics Market on the Rise Owing to Alarming Transmission of DNA Viruses among Global Population


Rising incidence of human papillomavirus (HPV) infections in developing as well as underdeveloped economies and increased seroprevalence have respectively driven the global human papillomavirus and cytomegalovirus therapeutics market over recent years, states a recently published report by Transparency Market Research. The report is titled “Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” and is available for sale on the company website.According to the research report, the global HPV therapeutics market was worth US$1.40 billion in 2013 and is projected to be worth US$2.34 billion in 2020, growing at a 7.7% CAGR during the report’s forecast period of 2014 to 2020. The CMV therapeutics market, on the other hand, stands to grow from US$0.87 billion in 2013 to US$0.92 billion in 2020 at a meager CAGR of 1.5% between 2014 and 2020.

The HPV therapeutics market is segmented on the basis of drug class, application, and pipeline drugs. In terms of revenue, immunomodulators were the dominant drug class in 2013 owing to cost-effectiveness, increased efficiency, and its nature as a non-invasive treatment. Application-wise, the segment of genital warts held the largest share of the HPV therapeutics market that year.Application, antiviral drugs, and pipeline drugs are the criteria based on which the CMV therapeutics market is segmented. Among the major antiviral drugs, ganciclovir and valganciclovir held the largest share of the CMV therapeutics market in 2013, while retinitis was the biggest application segment of the CMV therapeutics market that year.

The global HPV and CMV therapeutics market is segmented into five major regions: North America, South America, Europe, Asia Pacific, and Rest of the World. North America led the global HPV and CMV therapeutics market in 2013 in term of revenue. The HPV market in the region is driven by a rise in the sexually active population, increase in diagnostic rate, and growing international migration. The CMV therapeutics market in North America is fueled by increasing cost of drugs, rise in organ transplant surgeries, and high risk of STDs. The South America and Asia Pacific region are both estimated to witness significant growth in the HPV and CMV therapeutics market by 2020.

Browse the full Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 report at http://www.transparencymarketresearch.com/hpv-cmv-therapeutics-market.html


Clinigen Group plc, Perrigo Company plc, Roche Holdings AG, Merck & Co., Inc., AbbVie, Inc., Actavis plc, and Valeant Pharmaceuticals International, Inc. are the companies profiled in the HPV and CMV therapeutics market report. The CMV therapeutics market was dominated by Roche AG in 2013, thanks to Valcyte being the sole branded formulation available in the market. The HPV therapeutics market was led by Valeant Pharmaceuticals in 2013, owing to the success of its leading brands Aldara, Zyclara, Efudex, and Carac.Each of the players featured in this report are profiled based on attributes such as company and financial overview, product portfolio, recent developments, and business strategies such as mergers and acquisitions, geographic expansions, R&D practices, collaborations and agreements, and product launches.


About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Tuesday, 19 May 2015

Rising Preference for Generic Drug Variants to Negatively Impact Global Kidney Cancer Drugs Market

According to the latest research report released by Transparency Market Research, the global kidney cancer drugs market is expected to grow consistently at a CAGR of 6.6% during the period between 2014 and 2020. The report titled “Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” forecasts that in 2013, the global kidney cancer drugs market was worth US$2.6 billion and with consistent growth, the market will be valued at US$4.5 billion by 2020.

Browse the full Kidney Cancer Drugs Market report at

According to the World Cancer Research Fund International, kidney cancer is the twelfth most common cancer in the world. Also known as Renal Cell Carcinoma (RCC), it is associated with smoking, obesity, and reduced physical activity. The report mentions that the rise in the reported cases of kidney cancer worldwide along with rising geriatric population will fuel the growth of the global kidney cancer drugs market. The report cites that the growth of the global kidney cancer drugs market will get fuelled by the approval and commercialization of novel molecules in treating kidney cancer. However, the high cost of the drugs will deter the growth of the global kidney cancer drugs market. The report predicts that the increasing preference of generic drug variants will negatively impact the global kidney cancer drugs market.

The report studies the global kidney cancer drugs market depending upon the major branded drug used by the patients. Votrient, Inlyta, Avastin, Torisel, Proleukin, Afinitor, Sutent, and Nexavar are the major branded drug segments of the global kidney cancer drugs market. In 2013, Sutent dominated the global kidney cancer drugs market with more than 30% of the market share. Sunitinib (marketed as Sutent by the drug-manufacturing giant Pfizer) has been often used as the first-line treatment for renal cell carcinoma. The report suggests that the high price of the drug is expected to slow down the growth of this drug segment and the segment will reflect a sluggish growth at 1.1% from 2012 to 2016 and at 2.1% CAGR from 2016 to 2020. Votrient is predicted to be the fastest growing segment of the global kidney cancer drugs market. It is projected to take a leap at 41.7% CAGR during the period between 2012 and 2016. The growth of this segment will slow down considerably from 2016 to 2020 to a CAGR of 8.9%.

The report segments the global kidney cancer drugs market on the basis of the potential pipeline drugs to be launched during the forecast horizon. Cabozantinib, AGS-003, Dovitinib, Opdivo, and Keytruda are some of the drugs expected to be launched and commercialized during the period between 2012 and 2016, thereby strengthening the overall global kidney cancer drugs market.

Browse the full Press Release Report:

Geographically, the report segments the global kidney cancer drugs market into four key regions: North America, Asia Pacific, Europe, and Rest of the World. North America was the largest region of the global kidney cancer drugs market, accounting for more than 45% share. Due to the U.S. being the largest pharmaceutical market worldwide, the overall cancer drugs market receives the highest revenue for each of the drug segments from the country. The U.S. accounts for more than 90% of the global kidney cancer drugs market in North America, followed by Canada, which fills up the remaining market share in the region. The report mentions that the kidney cancer drugs market in Asia Pacific region will grow at a CAGR of 6% due to the rising demand from countries such as Australia, Japan, New Zealand, and China.


The global kidney cancer drugs market is highly consolidated with GlaxoSmithKline, Novartis AG, and Pfizer Inc. being some of the key players. Pfizer dominated more than 40% of the global kidney cancer drugs market in 2013.


About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.


Posted by at No comments:
Labels:

Transparency Market Research Projects U.S. Vaccine Market to be Valued at USD 17.4 billion by 2018

Data from a new report published by Transparency Market Research “U.S. Vaccine Market - U.S. Industry Analysis, Size, Share, Growth, And Forecast, 2012 - 2018", estimates the U.S. vaccine market to be worth USD 12.8 billion in 2012 and further expected to reach USD 17.4 billion by 2018, growing at a CAGR of 5.3% from 2012 to 2018.

Browse Full U.S. Vaccine Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/us-vaccine-market.html


Vaccines for different disorders and illnesses are included among the leading earners in the pharmaceutical industry. Over the recent years, enhanced research and development in this market has led to the production of better-quality and effective drugs and vaccines to treat various illnesses. The vaccine sales in U.S. are growing rapidly at a faster rate as compared to the other prescription medicines in the market. U.S. has showed a substantial revenue growth in the vaccine production market increasing the enormity of this industry as well.

The vaccine sales are chiefly resistive to the generic competition that is quoting drug makers billions of dollars in revenues on each of their top-selling vaccine treatments. Moreover, government supporting agencies are unfailing buyers of the vaccine products both in the U.S., as well as across the globe. Hence, U.S. is focused on continuing to lead the global vaccine market amongst other markets in the world. This drive is also due to the rising prevalence of infectious diseases in animals and humans, and improvements seen in the biotechnology sector across U.S.

According to the industry best market research firms’ surveys, many U.S. pediatricians claimed that over half of the U.S. population have parental concerns about general vaccines and child immunization. It is for such reasons, pediatric vaccine segment in the U.S. human vaccine market takes pride in holding the highest market share, as well as high growth rate because of government compulsion for child immunization. The adult & adolescent vaccine market in the
U.S. is expected to grow judiciously over the next six years due to increasing awareness for human papillomavirus (HPV) and other viral diseases.

On the other hand, the livestock vaccine is another leading segment across the U.S. Due to an increased awareness towards protecting infectious diseases in cattle, rising vaccination to prevent breeding animals against illnesses and disorders, and organizing the entire dairy sector, this market accounted for 58.1% of the total shares in 2012. The Bovine vaccine sector in the United States is considered to be the largest revenue generating sector in the present day.

Browse Full Press Release Report:

However, in 2011, the feline vaccine and canine vaccine also accounted for approximately 95.1% shares in the overall U.S. companion animal vaccine market.

This report includes more information about the generalized overview of the U.S. vaccine market including definitions, applications, and global market industry structure. It discusses the ephemeral shelf-life of certain vaccines available in the market and how they will have a negative impact on the overall market size and growth. However, the report also includes the market analysis of the overall vaccine industry that has multinational firms working on huge product pipeline in order to overcome all the shortcomings and restraints. The report provides extensive analysis of the U.S. vaccine market and the factors that will further revolutionize this industry towards a massive growth.

Among all the geographical regions, U.S. Vaccine Market is considered to be the largest in the history of vaccine. Since 2011, there have been some significant leading producers of human vaccine for the U.S. market and the names included are Merck, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Sanofi-Pasture and Novartis. Similarly, for the animal vaccine market, the leading producers of animal vaccine for the U.S. market includes Merial (Sanofi-Aventis), Pfizer Animal Health, Novartis Animal Health, and Intervet/Schering-Plough (Merck).


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Posted by at No comments:
Labels:

Sunday, 17 May 2015

U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market Expected to Reach USD 10.2 Billion in 2020

According to a new market report published by Transparency Market Research “U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” the U.S., Europe and Japan orthopedic soft tissue surgical procedures market was valued at USD 7.3 billion in 2013 and is estimated to reach a market worth of USD 10.2 billion in 2020 growing at a CAGR of 4.9% from 2014 to 2020.

Browse the full U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market report at http://www.transparencymarketresearch.com/soft-tissue-repair-sports-medicine.html


The report on U.S., Europe and Japan orthopedic soft tissue surgical procedures market studies market size of rotator cuff repair, vaginal prolapse, lateral epicondylitis, achilles tendinosis repair, gluteal tendon repair and anterior cruciate ligament reconstruction (ACL). Rising number of sport related injuries coupled with growth of active aging population in the developed regions would boost the demand of orthopedic soft tissue surgeries. According to the American Academy of Orthopaedic Surgeons (AAOS) and the American Orthopaedic Society for Sports Medicine, over 150,000 anterior cruciate ligament (ACL) injuries occur each year in the U.S. alone. Additionally, introduction of high cost and innovative surgical repair products and increasing incidence of obesity have raised the demand of orthopedic surgeries thereby propelling market growth. For example, Biomet, Inc. launched JuggerKnotless Soft Anchor device in July 2014 which featured company’s all-suture anchor technology. This device enables the repair of rotator cuff damage with better restoration and high efficacy. Growing acceptance of minimally invasive soft tissue surgical techniques (arthroscopy procedures) has enabled the completion of soft tissue surgeries in shorter time with lesser complication rates. This factor is also increasing the uptake of soft tissue surgeries. However, asymptomatic nature of soft tissue surgeries and high threat from conservative therapy are anticipated to restrain the market growth.

In terms of various surgical procedures ACL reconstruction accounted for the largest share of the market in 2013. ACL reconstruction is also likely to retain its dominant position in the future as it is the most common knee injury that requires surgical intervention. Rising participation in sports such as football, basketball and others along with increasing number of patients opting for reconstructive surgeries due to introduction of minimally invasive surgeries would fuel the growth of this segment. Similarly, launch of bio-absorbable which nullifies the risk related to implant removal would also aid in increasing the market size for ACL reconstruction. The market of gluteal tendon repair accounted for the smallest share in 2013 owing to large pool of patients being treated by non-operative methods such as pain killers and steroid injection for this condition.
Browse the full Press Release Report:

soft-tissue-repair-sports-medicine-market

Geographically, the U.S. orthopedic soft tissue surgical procedures market captured major market revenue in 2013 and is expected to dominate the market during the forecast period from 2014 to 2020. Rising population base, increasing urge to stay healthy among geriatric population and improving healthcare coverage would contribute towards the growth of orthopedic soft tissue surgical procedures in this region. The orthopedic soft tissue surgical procedures market in Europe is anticipated to grow at a CAGR of 4.7% due to increasing number of sports related injuries. According to “Injuries in the European Union” published by EuroSafe, sports related injuries accounted for around 14% of the total injuries in the European Union. Similarly, a survey conducted by the professionals in Europe in 2010 concluded that the annual prevalence of people consulting for shoulder pain was 2.4% in the U.K.; most of these were attributed to rotator cuff injuries. Thus, increasing incidences of soft tissue injuries would propel the market growth in this region.

The orthopedic soft tissue surgical procedures market is fragmented in nature and is dominated by players, namely Arthrex, Inc., Smith & Nephew, plc., DePuy Synthes, Inc., Stryker Corporation., CONMED Corporation, and ArthroCare Corporation. Of all these, Arthrex was identified as the largest player in this market in 2013 followed by Smith & Nephew and Depuy Synthes, Inc.


The U.S., Europe and Japan orthopedic soft tissue surgical procedures market is segmented as follows:
U.S. Orthopedic Soft Tissue Surgical Procedures Market, by Indications
Rotator Cuff Repair
Vaginal Prolapse
Lateral Epicondylitis
Achilles Tendinosis Repair
Gluteal Tendon Repair
Anterior Cruciate Ligament (ACL) Reconstruction
Europe Orthopedic Soft Tissue Surgical Procedures Market, by Indications
Rotator Cuff Repair
Vaginal Prolapse
Lateral Epicondylitis
Achilles Tendinosis Repair
Gluteal Tendon Repair
Anterior Cruciate Ligament (ACL) Reconstruction
Japan Orthopedic Soft Tissue Surgical Procedures Market, by Indications
Rotator Cuff Repair
Vaginal Prolapse
Lateral Epicondylitis
Achilles Tendinosis Repair
Gluteal Tendon Repair
Anterior Cruciate Ligament (ACL) Reconstruction


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.


Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Posted by at No comments:
Labels:

Dilated Cardiomyopathy Therapeutics Market Expected to Reach USD 0.33 billion Globally in 2020

According to a new market report published by Transparency Market Research "Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020," the global dilated cardiomyopathy market was valued at USD 651.0 million in 2013 and is estimated to reach USD 328.6 million in 2020 declining at a CAGR of (7.0%) from 2014 to 2020.

Browse the full report Dilated Cardiomyopathy Therapeutics Market at http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html


Dilated cardiomyopathy (DCM) is one of the myocardium disorders associated with cardiac dysfunction. Hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathies represent the four major types of cardiomyopathies, and the others fall under unclassified category. DCM accounts for one of the major causes of heart failure and is characterized by the presence of dilated heart muscles which lead to enlargement of the heart. This in turn, hampers blood pumping capacity of the heart and with time, DCM spreads to the right ventricle, atria and ultimately results in heart failure. The occurrence of dilated cardiomyopathy in males is more prevalent than in females at a ratio of 3:1. Patients with mild DCM can lead normal lives by regular intake of medication along with some lifestyle changes, while patients with severe DCM need a heart transplant.

Oral medications and implantable medical devices constitute the key treatment options for DCM. Oral medications decrease the size of the heart by acting against high blood pressure and coronary artery disease. Devices implanted in DCM patients refer to implantable cardioverter–defibrillator (ICD), pacemakers (biventricular pacing) and heart pumps. The dilated cardiomyopathy therapeutics market is anticipated to decline throughout the forecast period from 2014 to 2020. This is majorly attributed to patent expirations, potential side effects of the drugs and increasing efficiency of alternative therapies.

The market for dilated cardiomyopathy therapeutics is segmented majorly by drug class and geography. The various drug classes considered include aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers and beta blockers. ACE inhibitors are considered as the first line of treatment in patients suffering from dilated cardiomyopathy, and these drugs help improve pumping capacity of the heart by decreasing the activity of rennin-angiotensin-aldosterone system (RAAS). The sales of ACE inhibitors are anticipated to reduce during the forecast period from 2014 to 2020 majorly due to patent expiration of the prominent drugs and increasing competition from generic drugs, which will further hamper market growth.

Aldosterone antagonists reduce cardiac activity and blood pressure. Eplerenone and spironolactone are the two major aldosterone antagonists used in the treatment of dilated cardiomyopathy. This drug class will record highest growth rate owing to their increased acceptance and increased survival rate of patients with DCM. Angiotensin II receptor blockers (ARBs) in combination with ACE inhibitors are usually preferred to treat dilated cardiomyopathy as these drugs block the RAAS pathway, thereby reducing the pressure exerted by the heart. Clinical trials have proven the successful effect of ARBs such as valsartan, losartan and candersartan against DCM. However, loss of patent exclusivity of major drugs followed by the increased efficiency of combination therapies in treatment of DCM might hamper market growth and result in declined sales in the forthcoming years.


Currently, there is no drug approved specifically for the treatment of dilated cardiomyopathy; however, the above mentioned drugs have been studied for their effectiveness in treatment of DCM that has lead to doctors prescribing these medications. This factor provides lucrative opportunity for the market payers to develop and commercialize specific drugs against dilated cardiomyopathy. Increasing efficiency of alternative therapies such as implantable medical devices and gene therapy might further play a role in decelerating market growth.

Major players competing in this market are Novartis International AG, Merck Co. & Inc., and AstraZeneca plc that together accounted for more than 70% of the total dilated cardiomyopathy therapeutics market revenue. Other players include Pfizer, Inc., Sanofi Aventis, GlaxoSmithKline plc and Valeant Pharmaceuticals, Inc. Increasing investments by market players towards the development of dilated cardiomyopathy drugs will favor market growth post their approval. For instance, Array BioPharma, Inc. (ARRY – 797), Celladon Corporation (MYDICAR) and Vericel Corporation (IXCELL-DCM, Catheter-DCM, IMPACT-DCM) constitute some of the companies whose drugs are in pipeline (phase I or Phase II).

Browse the full Press Release report:

The global dilated cardiomyopathy therapeutics market is segmented into the following categories:

Dilated cardiomyopathy therapeutics market, by drug class
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Beta-blockers
Dilated cardiomyopathy therapeutics market, by pipeline drugs
ARRY-797
ixCELL-DCM
MYDICAR
OR-1
CAP-1002
Dilated cardiomyopathy therapeutics market, by geography
North America
Europe
Asia Pacific
Rest of the World (RoW)


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Posted by at No comments:
Labels:

Friday, 15 May 2015

Active Pharmaceutical Ingredients Market Growing at a CAGR of 6.5% between 2014 and 2020


Diseases and epidemics are nature’s way to control population. With the ever-increasing number of deaths being reported due to various chronic diseases as well as newly diagnosed cases, the global active pharmaceutical ingredients (API) market has a huge demand to meet.

Browse Full Global Active Pharmaceutical Ingredients Market Report With Complete TOC @ http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html


Global API Market to be Valued at US$185.9 Billion by 2020

In 2013, the global API market was valued at US$119.7 billion. It is expected to grow at a CAGR of 6.5% from 2014 to 2020 and reach a valuation of US$185.9 billion by 2020. On the basis of therapeutic area, the API market is segmented into non-steroidal anti-inflammatory drugs (NSAIDS), oncology drugs, anti-diabetic drugs, cardiovascular drugs, central nervous system drugs, musculoskeletal drugs, and others.

Oncology Segment Will Be the Fastest Growing Drug Segment

Due to the prevalent sedentary lifestyle and growing aging population, cardiovascular diseases and diseases related to the central nervous system are rising. In 2013, the market revenue share for cardiovascular drugs was the highest. As per the data provided by the World Health Organization, in 2012, cancer alone led to 8.2 million deaths worldwide along with 14 million newly diagnosed cases. In response to this, the oncology drug segment will have the fastest growth in the API market during the period from 2014 to 2020. High potency active pharmaceutical ingredients (HPAPIs) are a component of most drugs in the oncology drug segment. So, the growth of the HPAPI market would be rapid to keep up with the growth of oncology drug segment.

Asia Pacific will Account for the Highest Growth from 2014 to 2020

In 2013, North America accounted for the majority share (35%) in the global API market. The API market in this region is expected to grow further. FDA approvals for the production of innovative drugs and growing awareness about the intake of generic medicines have led to the growth of the API market in North America.

The Asia Pacific region is expected to achieve the highest growth in the global API market in the period from 2014 to 2020. The API market has a huge demand from the Asia Pacific region because of the population demographics in this geography. In terms of production, the global API market has shifted to Asia Pacific because of the availability of cheap labor, tax benefits provided by the governments for manufacturing, and less regulations on the markets.

China and India are the frontrunners in API production. API manufacturing companies from North America and Europe have invested substantially in these two countries. In North America, stringent pharmaceutical regulations, such as the U.S. Drug Quality and Security Act, have to be met with. This has caused a slight decrease in the growth of the API market in this region.

Browse Full Press Release Report:


Costlier Production of Biological Drugs Hampers Segment

Compared to synthetic APIs, biological drugs are costlier because they are difficult to replicate and have difficult manufacturing requirements. Enhanced technological support has resulted in the production of biosimilars, which are not the exact replication of innovator drugs, but are efficient and safe. This has led to a big opportunity for biopharmaceutical companies like Novartis in the API market.

However, production of biosimilars requires approvals from the respective countries. The European Union has set the trend by approving biosimilars and the WHO has followed the approval guidelines similar to the European Union. As a first, the U.S. has approved the biosimilar Filgrastim (2015), which shows its interest in expanding its biological API market.

Key Players in Active Pharmaceutical Ingredients Market

The key players competing in the global API market include Cambrex Corporation, Boehringer Ingelheim Group, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., BASF SE, Hospira Inc., Lonza Group, Mylan, Inc., Novartis AG, Actavis plc, Teva Pharmaceutical Industries Ltd., and Wuxi Apptec.

Request a Brochure of this Report

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)